Patents
Endothelialization of vascular surfaces
Patent Number: 7,172,758Endothelial injury may be induced by numerous means. One clinically relevant situation is endothelial injury caused by balloon injury during percutaneous transluminal coronary balloon angioplasty. This injury causes restenosis, which eventually requires re-intervention. This patent teaches ways of accelerating the healing of the injured tissue by essentially “sticking” the endothelial...
Inventors: Colb; A. Mark (West Roxbury, MA), Gold; Herman K. (Brookline, MA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday January 29th, 2002
Method for regulating neuron development and maintenance
Patent Number: 7,173,001Leukemia inhibitory factor (LIF) is a member of the IL-6 family of cytokines that was originally identified based on its ability to induce differentiation of myeloid leukemia cells. Its homology ciliary neurotrophic factor (CNTF) has been shown to support the resistance to apoptosis of numerous types of peripheral and central nervous system neurons, as well as induce new neurite formation after...
Inventors: Bartlett; Perry (North Carlton, AU), Murphy; Mark (Fitzroy, AU)
Assignee: Zenyth Operations Pty Ltd. (Richmond, AU)
Date of First Priority Issue: Thursday November 19th, 1992
Composition and method for treating graft-versus-host disease
Patent Number: 7,173,016Graft versus host disease (GVHD) is one of the major limitations of bone marrow, or for that matter, any type of allogeneic hematopoietic stem cell transplant. Essentially, GVHD is the result of donor derived T cells attacking the allogeneic recipient. Previously attempts were made to reduce GVHD by “purging” the stem cell graft of T cells using various antibodies or tissue culture...
Inventors: DiMartino; Jorge (San Carlos, CA), Nelson; John Tippett (Danville, CA)
Assignee: Mayne Pharma (USA); Inc. (Paramus, NJ)
Date of First Priority Issue: Friday October 12th, 2001
Methods to mobilize progenitor/stem cells
Patent Number: 7,169,750The reason why bone marrow cells home into the bone after intravenous administration is because a continuous production of Stromal Derived Factor-1 (SDF-1) by the bone marrow stromal compartments. The gradient of SDF-1 is also retains the early CD34+ bone marrow hematopoietic stem cells in the bone marrow. The current patent covers compositions of matter that inhibit the interaction...
Inventors: Bridger; Gary (Bellingham, WA), Abrams; Michael J. (Custer, WA), Henson; Geoffrey W. (Ferndale, WA), MacFarland; Ronald T. (Vancouver, CA), Calandra; Gary B. (Cresco, PA)
Assignee: Anormed, Inc. (Langley, CA)
Date of First Priority Issue: Sunday February 4th, 2007
Serum-free media for chondrocytes and methods of use thereof
Patent Number: 7,169,610This patent discloses methods of expanding chondrocyte precursors and differentiated chondrocytes ex vivo without the use of animal derived tissue culture components. The patent teaches the use of growth factors such as platelet derived growth factor, together with specific lipids, such as stearic acid, myristic acid, oleic acid, linoleic acid, palmitic acid, palmitoleic acid, arachidonic...
Inventors: Brown; Liesbeth Maria E. (West Newton, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Date of First Priority Issue: Friday January 25th, 2002
Bone marrow cell differentiation
Patent Number: 7,169,608The patent describes a simple method of inducing differentiation of bone marrow into islets by a simple two step culture approach involving an initial culture in low concentration of glucose (at least 3 days) followed by a subsequent culture in high concentration of glucose (at least 7 days). The resulting cells generate insulin in response to sugar, and are capable of preventing diabetes...
Inventors: Petersen; Bryon E. (Gainesville, FL), Oh; Seh-hoon (Gainesville, FL)
Assignee: University of Florida Research Foundation, Inc. (Gainesville, FL)
Date of First Priority Issue: Friday October 18th, 2002
Methods of controlling proliferation and differentiation of stem and progenitor cells
Patent Number: 7,169,605Ex vivo expansion of stem cells offers the possibility of using autologous cells for the treatment of diseases ranging from hematopoietic disorders to post myocardial infarction cardiac regeneration. Stem cell therapy with adult cells is often limited by the fact that it is difficult to obtain high enough numbers of cells for performing repeated administration. Additionally, stem cells from...
Inventors: Peled; Tony (Mevaseret Zion, IL), Fibach; Eitan (Mevaseret Zion, IL), Treves; Avi (Mevaseret Zion, IL)
Assignee: Gamida Cell Ltd. (Jerusalem, IL)
Date of First Priority Issue: Tuesday February 17th, 1998
High concentration white blood cells as a therapeutic product
Patent Number: 7,169,547This patent covers methods of preserving cord blood mononuclear cells. The approach taken here is focused on the collection and preservation of white blood cells from cord blood as a "therapeutic product". The cells appear to be stored in plasma from the same source as the donor and this may be one of the reasons why this patent was issued in light of the pre-existing
Assignee: New York Blood Center, Inc. (New York, NY)
Date of First Priority Issue: Monday December 5th, 1994
Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
Patent Number: 7,166,280Heart failure has been one of the main areas of stem cell research. Specifically, stem cells have previously been used clinically both for treatment of immediate post myocardial infarction (primarily to inhibit scar tissue and subsequent remodelling), as well as in patients with cardiac degeneration in absense of a myocardial infarct. The current patent is very interesting since it claims...
Inventors: Franco; Wayne P. (Rocky Hill, CT)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Thursday April 6th, 2000
Method of culturing cells to produce a tissue sheet
Patent Number: 7,166,464The ability to generate monolayers of cells is important for a variety of tissue engineering applications. Most notably is the need to generate monolayers that can be placed on medical devices such as stents in order to allow increased compatibility and decreased rates of restenosis. The current patent teaches ways of culturing cells, including stem cells, in a monolayer and methods of...
Inventors: McAllister; Todd N. (Novato, CA), L'Heureux; Nicolas (Corte Madera, CA)
Assignee: Cytograft Tissue Engineering, Inc. (Novato, CA)
Date of First Priority Issue: Tuesday December 11th, 2001